ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

PIRS Pieris Pharmaceuticals Inc

9.7003
-0.3898 (-3.86%)
Jun 17 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 5,793
Bid Price 9.70
Ask Price 10.25
News -
Day High 9.90

Low
9.31

52 Week Range

High
73.60

Day Low 9.511
Share Name Share Symbol Market Stock Type
Pieris Pharmaceuticals Inc PIRS NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.3898 -3.86% 9.7003 16:42:31
Open Price Low Price High Price Close Price Previous Close
9.81 9.511 9.90 9.7001 10.0901
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
293 5,793 US$ 9.80 US$ 56,798 - 9.31 - 73.60
Last Trade Type Quantity Price Currency
16:42:31 formt 700 US$ 9.7003 USD

Pieris Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
958.86M 98.85M - 42.81M -24.54M -0.25 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Pieris Pharmaceuticals News

Date Time Source News Article
5/15/202415:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/09/202407:00Edgar (US Regulatory)Form 8-K - Current report
2/14/202415:37Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
2/14/202412:12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
2/14/202408:19Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
2/02/202408:59Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
12/21/202315:30Edgar (US Regulatory)Form 8-K - Current report
11/14/202315:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/31/202315:15Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]
8/10/202316:04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee..
8/10/202315:24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
7/18/202308:15Edgar (US Regulatory)Form 8-K - Current report
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No PIRS Message Board. Create One! See More Posts on PIRS Message Board See More Message Board Posts

Historical PIRS Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week10.1010.82999.51110.155,318-0.3997-3.96%
1 Month11.0011.379.3110.275,494-1.30-11.82%
3 Months15.5216.009.3113.46260,166-5.82-37.50%
6 Months13.2022.329.3114.45426,322-3.50-26.51%
1 Year73.6073.609.3119.811,294,458-63.90-86.82%
3 Years280.80492.009.31157.86985,220-271.10-96.55%
5 Years348.80496.009.31222.261,209,280-339.10-97.22%

Pieris Pharmaceuticals Description

Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States.

Your Recent History

Delayed Upgrade Clock